InspireMD (STU:II2) 3-Year RORE % : -2.31% (As of Mar. 2026)


STU:II2 InspireMD Inc STU:II2
42 GF Score
Price €0.60
GF Value €1.52
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD 3-Year RORE %?

InspireMD STU:II2 +2.56% 42 3-Year RORE % is -2.31 as of Mar. 2026. GuruFocus rates STU:II2 with a GF Score™ of 42/100 and a GF Value™ of €1.52 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 782 Medical Devices & Instruments companies, InspireMD ranks worse than 127877.11% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. InspireMD's 3-Year RORE % for the quarter that ended in Mar. 2026 was -2.31%.

The industry rank for InspireMD's 3-Year RORE % or its related term are showing as below:

STU:II2's 3-Year RORE % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -4.23 vs STU:II2: -2.31

InspireMD  (STU:II2) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


InspireMD 3-Year RORE % Related Terms


InspireMD 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for InspireMD's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD 3-Year RORE % Chart

InspireMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.18 -57.04 -15.55 -38.35 -11.87

InspireMD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.78 -34.03 -23.61 -11.87 -2.31

STU:II2 vs TELA, BDMD, PAVM: 3-Year RORE % Comparison

For the Medical Devices subindustry, InspireMD's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where InspireMD's 3-Year RORE % falls into.


STU:II2
42GF Score
InspireMD Inc STU:II2
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD 3-Year RORE % Calculation

InspireMD's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.628--0.675 )/( -2.035-0 )
=0.047/-2.035
=-2.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -2.31 mean?
InspireMD (STU:II2) has a 3-Year RORE % of -2.31 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on InspireMD and its competitors. According to the industry distribution chart, InspireMD ranks #999999 out of 782 companies in the Medical Devices & Instruments industry.
Is InspireMD's 3-Year RORE % too high?
InspireMD's current 3-Year RORE % is -2.31. Based on the distribution chart, InspireMD ranks #999999 out of 782 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InspireMD has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's 3-Year RORE % compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #999999 out of 782 companies for 3-Year RORE %. This places InspireMD in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on InspireMD and its competitors. InspireMD's current 3-Year RORE % is -2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.52, compared to a current price of €0.60 — trading 60.5% below its estimated fair value. The current 3-Year RORE % is -2.31. InspireMD's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For InspireMD (STU:II2), the current 3-Year RORE % is -2.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.60 is trading 60.5% below its estimated GF Value™ of €1.52. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • 3-Year RORE %: -2.31
  • GF Value™: €1.52 vs. price of €0.60 (60.5% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
42GF Score

Get the complete analysis for STU:II2

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€1.52
GF Value